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Abstract 
25I-NBOMe, a new psychoactive substance, is a potent 5-HT2A receptor agonist with strong 
hallucinogenic potential. Recently, it was involved in several fatal and non-fatal intoxication cases. 
The aim of the present work was to study its phase I and II metabolism and its detectability in urine 
screening approaches. After application of 25I-NBOMe to male Wistar rats, urine was collected 
over 24h. The phase I and II metabolites were identified by LC-HR-MS/MS in urine after suitable 
workup. For the detectability studies, standard urine screening approaches (SUSA) by GC-MS, LC-
MSn, and LC-HR-MS/MS were applied to rat and also to authentic human urine samples submitted 
for toxicological analysis. Finally, an initial CYP activity screening was performed to identify CYP 
isoenzymes involved in the major metabolic steps. 25I-NBOMe was mainly metabolized by O-
demethylation, O,O-bis-demethylation, hydroxylation, and combinations of these reactions as well 
as by glucuronidation and sulfation of the main phase I metabolites. All in all, 68 metabolites could 
be identified. Intake of 25I-NBOMe was detectable mainly via its metabolites by both LC-MS 
approaches, but not by the GC-MS SUSA. Initial CYP activity screening revealed the involvement 
of CYP1A2 and CYP3A4 in hydroxylation and CYP2C9 and CYP2C19 in O-demethylation. The 
presented study demonstrated that 25I-NBOMe was extensively metabolized and could be detected 
only by the LC-MS screening approaches. Since CYP2C9 and CYP3A4 are involved in initial 
metabolic steps, drug-drug interactions might occur in certain constellations. 
 
Keywords: designer drugs; 25I-NBOMe; metabolism; cytochrome-P450; LC-MSn; LC-HR-
MS/MS 
 
Page 2 of 43Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
3 
 
Introduction 
 
In recent years, with N-2-methoxybenzyl phenethylamine (NBOMe) derivatives a new class of so-
called New Psychoactive Substances (NPS) appeared on the drug scene. They are derived from a 
class of the well-known potent hallucinogenic phenethylamines, the so-called 2Cs [1]. The NBOMe 
derivatives are very potent serotonin receptor agonists as figured out in structure-activity 
relationship studies [2, 3]. Thus, they have a high potential for hallucinogenic effects with the risk 
of serotonergic toxicity. Among others, 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxy-
phenyl)methyl]ethanamine (25B-NBOMe, 2C-B-NBOMe), 2-(4-chloro-2,5-dimethoxyphenyl)-N-
[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe, 2C-C-NBOMe), and 2-(4-iodo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe, 2C-I-NBOMe) have 
been sold and consumed as so-called research chemicals. For example, 25I-NBOMe is usually 
consumed in form of blotter papers, powder, or as nose sprays at very low doses of 0.5-1.5 mg 
(https://www.erowid.org). In the meantime, most of them have been scheduled in many countries 
considering the common use and partly fatal poisoning cases [4-9]. In such cases, the drugs must be 
screened and quantified in clinical and forensic laboratories. Several procedures for quantification 
of NBOMe’s in serum specimen have been published [4, 10], but if the consumed drugs are 
unknown, screening procedures, mostly in urine, are initially applied. One requisite for developing 
screening approaches reliably detecting such lipophilic drugs is to know the analytical targets in 
body samples [11-13]. Thus, the metabolism should be studied first. This is also relevant for 
assessing of drug-drug interactions or toxic risks. Such studies have been comprehensively 
performed for the underlying 2C analogues [14-21]. However, there is no systematic study 
available on the metabolism or detectability in urine of NBOMe derivatives. Among the NBOMe 
derivatives, 25I-NBOMe seems to be the most commonly used drug. Stellpflug et al. [7] described 
the possible presence of three O-demethyl- isomers but no detailed metabolism studies were done. 
Therefore, the aim of the present study was to elucidate the metabolism of 25I-NBOMe in rats and 
humans using Orbitrap (OT)-based LC-HR-MS/MS. Furthermore, the detectability of 25I-NBOMe 
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and its metabolites by the authors’ standard urine screening approaches (SUSA) by GC-MS [22], 
LC-MSn [23], or LC-HR-MS/MS (Helfer et al., submitted) should be studied. 
 
 
Experimental 
 
Chemicals and reagents 
 
25I-NBOMe hydrochloride was purchased by LGC Standards (Wesel, Germany). Isolute HCX 
cartridges (130 mg, 3 mL) were obtained from Biotage (Uppsala, Sweden), isocitrate and isocitrate 
dehydrogenase from Sigma (Taufkirchen, Germany), NADP+ from Biomol (Hamburg, Germany), 
acetonitrile (LC-MS grade), ammonium formate (analytical grade), formic acid (LC-MS grade), 
methanol (LC-MS grade), mixture (100,000 Fishman units/mL) of glucuronidase (EC No. 3.2.1.31) 
and arylsulfatase (EC No. 3.1.6.1) from Helix Pomatia, and all other chemicals and reagents 
(analytical grade) from VWR (Darmstadt, Germany). The baculovirus-infected insect cell 
microsomes (Supersomes) containing 1 nmol/mL of human cDNA-expressed CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (2 nmol/mL), CYP3A4, or CYP3A5 
(2 nmol/mL), and pooled human liver microsomes (pHLM, 20 mg microsomal protein/mL, 400 
pmol total CYP/mg protein) were obtained from BD Biosciences (Heidelberg, Germany). After 
delivery, the microsomes were thawed at 37°C, aliquoted, snap-frozen in liquid nitrogen, and stored 
at -80°C until use.  
 
Urine samples 
 
According to the usual study design [24], the investigations were performed using rat urine samples 
from male Wistar rats (Charles River, Sulzfeld, Germany) for toxicological diagnostic reasons 
according to the corresponding German law. The compound was administered in an aqueous 
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suspension by gastric intubation of a single 4 mg/kg body weight (BW) dose for identification of 
the metabolites and of 0.05 and 0.1 mg/kg BW) for screening. The rats were housed in metabolism 
cages for 24 h, having water ad libitum. Urine was collected separately from the feces over a 24 h 
period. Blank urine samples were collected before drug administration to check whether the 
samples were free of interfering compounds. The samples were directly analyzed and then stored at 
-20°C.  
An authentic human urine sample after unintentional intake of 25I-NBOMe submitted to the 
authors’ laboratory for toxicological diagnostics was also analyzed. 
 
Sample preparation for identification of phase I metabolites by LC-HR-MS/MS 
 
According to published procedures [24], 2 mL of urine was adjusted to pH 5.2 with acetic acid (1 
M, approximately 50 µL) and incubated at 56 °C for 2 h with 50 µL of a mixture of glucuronidase 
and arylsulfatase. The urine sample was then loaded on an HCX cartridge previously conditioned 
with 1 mL of methanol and 1 mL of water. After passage of the sample, the cartridge was washed 
with 1 mL of water, 1 mL of 0.01 M hydrochloric acid, and again with 1 mL of water. The acidic 
and neutral compounds (eluate A) were eluted with 1 mL of methanol into a 1.5 mL reaction vial 
and the basic compounds (eluate B) with 1 mL of a freshly prepared mixture of methanol/aqueous 
ammonia 32% (98:2, v/v), respectively. The eluates were evaporated to dryness under a stream of 
nitrogen and reconstituted with 50 µL of a mixture of eluent A and B (1:1, v/v) for LC-HR-MS/MS 
analysis. A 10-µL aliquot of each extract was then injected onto the LC-HR-MS/MS. 
 
Sample preparation for identification of phase II metabolites by LC-HR-MS/MS 
 
According to published procedures [24], 100 µL of urine was mixed with 500 µL of acetonitrile for 
precipitation. After shaking and centrifugation, the supernatant was gently evaporated to dryness 
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and reconstituted in 50 µL of a mixture of 10 mM aqueous ammonium formate buffer (pH 3) and 
acetonitrile (1:1, v/v) and 10 µL injected onto the LC-HR-MS/MS system. 
 
Microsomal incubations for initial CYP activity screening studies 
 
According to standard procedures [24, 25], microsomal incubations were performed at 37°C at a 
concentration of 25 µM 25I-NBOMe with the CYP isoenzymes (75 pmol/mL, each) CYP1A2, 
CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, or CYP3A5 for 
30 min as well as HLM (20 mg protein/mL) as positive control. Besides enzymes and substrates, 
the incubation mixtures (final volume, 50 µL) contained 90 mM phosphate buffer (pH 7.4), 5 mM 
Mg2+, 5 mM isocitrate, 1.2 mM NADP+, 0.5 U/mL isocitrate dehydrogenase, and 200 U/mL 
superoxide dismutase. For incubations with CYP2A6 or CYP2C9, phosphate buffer was replaced 
with 45 mM and 90 mM Tris buffer, respectively, according to the Gentest manual. Reactions were 
initiated by addition of the microsomes and stopped with 50 µL of ice-cold acetonitrile, containing 
5 µM trimipramine-d3 as internal standard. The solution was centrifuged for 2 min at 14,000×g; 70 
µL of the supernatant phase were transferred to an autosampler vial and 10 µL injected onto the 
LC-HR-MS/MS system. 
 
LC-HR-MS/MS apparatus for identification of phase I and II metabolites and CYP initial 
screening 
 
According to published procedures [26], the extracts were analyzed using a ThermoFisher 
Scientific (TF, Dreieich, Germany) Accela LC system consisting of a degasser, a quaternary pump 
and an HTC PAL Autosampler (CTC Analytics AG, Zwingen, Switzerland), coupled to a TF Q-
Exactive system equipped with a heated electrospray ionization (HESI)-II source. The instrument 
was used in positive ionization mode or in positive/negative switching mode. Mass calibration was 
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done prior to analysis according to the manufacturer’s recommendations using external mass 
calibration. 
Gradient elution was performed on a TF Accucore PhenylHexyl column (100 mm x 2.1 mm, 
2.6 µm). The mobile phases consisted of 2 mM aqueous ammonium formate containing formic acid 
(0.1%, v/v) and acetonitrile (1%, v/v) (pH 3, eluent A) and ammonium formate solution with 
acetonitrile:methanol (50:50, v/v) containing formic acid (0.1%, v/v) and water (1%, v/v) (eluent B). 
The gradient and flow rate were programmed as follows: 0-1 min hold 1% B, 1-16 min 5% B to 
95% B, 16-18 min hold 95% B, and 18-20 min hold 1% B, constantly at 500 µL/min. 
The HESI-II source conditions were as follows: sheath gas, 60 arbitrary units (AU); auxiliary 
gas, 10 AU; spray voltage, 3.00 (positive polarity) and -4.00 kV (negative polarity); heater 
temperature, 320°C; ion transfer capillary temperature, 320°C; and S-lens RF level, 60.0. Mass 
spectrometry was performed in positive polarity mode for the eluate B and in positive/negative 
polarity switch mode for the eluate A using full scan (FS) data and a subsequent data dependent 
acquisition (DDA) mode with an inclusion list on the masses of the metabolites.  
The settings for FS data acquisition were as follows: resolution, 35,000; microscans, 1; 
automatic gain control (AGC) target, 1e6; maximum injection time (IT), 120 ms; and scan range, 
m/z 70 – 1000. The settings for the DDA mode (loop count 5) with an inclusion list for the expected 
metabolites were as follows: precursor ions, transferred to an exclusion list for 1 s (dynamic 
exclusion); resolution, 17,500; microscans, 1; AGC target, 2e5; maximum IT, 250 ms; isolation 
window, 1.0 m/z; HCD with stepped normalized collision energy (NCE), 17.5, 35, and 52.5%; 
spectrum data type, profile; and underfill ratio, 0.1%. 
For analyzing the initial CYP activity screening, the MS settings and the mobile phases were 
the same. The inclusion list only contained the masses of corresponding metabolites (m/z 308.0148, 
414.0561, and 444.0666). The gradient and flow rate were as follows: 0-0.5 min hold 20% B, 0.5-
2.5 min 20% B to 50% B, 2.5-4 min hold 50% B, 4-5.5 min 50% B to 80%, 5.5-6 min hold 80% B, 
and 6-7 min hold 20% B, constantly at 500 µl/min. 
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GC-MS SUSA 
 
The GC-MS SUSA was performed as described elsewhere [22].  
 
LC-MSn SUSA 
 
In accordance to Wissenbach et al. [23, 27], the urine samples (100 µL) were worked up by 
precipitation as described for the identification of phase II metabolites. The samples were separated 
and analyzed using a TF LXQ linear ion trap MS equipped with a HESI II source and coupled to a 
TF Accela LC system consisting of a degasser, a quaternary pump, and an autosampler. Gradient 
elution was performed using a TF Hypersil Gold (150 x 2.1 mm, 1.9 µm) column and 10 mM 
aqueous ammonium formate buffer containing formic acid (0.1%, v/v) as mobile phase A and 
acetonitrile containing formic acid (0.1%, v/v) as mobile phase B. The gradient and flow rate were 
programmed from 98% to 0% A at 500 µL/min within 21 min (injection volume 10 µL). DDA was 
conducted on precursor ions selected from MS1. MS1 was performed in FS mode (m/z 100-800). 
MS2 and MS3 were performed in DDA mode: four DDA MS2 scan filters were chosen to provide 
MS2 on the four most intense signals from MS1 and additionally, eight MS3 scan filters were chosen 
to record MS3 on the most and second most intense signals from the MS2. MS2 spectra were 
collected with a higher priority than MS3 spectra. Wideband NCE with collision induced 
dissociation were 35% for MS2 and 40% for MS3.  
TF ToxID 2.1.1 was used for automatic target screening in the MS2 screening mode. The 
settings were as follows: retention time (RT) window, 20 min; RT, 0.1 min; signal threshold, 100 
counts; search index, 600; reverse search index, 700. ToxID was run automatically after file 
acquisition using an Xcalibur processing method starting both software tools [28]. The MS2 and 
MS3 reference spectra were recorded in urine after the above-mentioned workup and analysis. They 
were confirmed by comparison with the corresponding LC-HR-MS/MS spectra. 
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LC-HR-MS/MS SUSA 
 
According to Helfer et al. (manuscript submitted), the same LC-HR-MS/MS apparatus was used as 
for the identification of phase I and II metabolites with gradient elution on a TF Accucore 
PhenylHexyl column (100 x 2.1 mm, 2.6 µm). The mobile phases consisted of 2 mM aqueous 
ammonium formate containing formic acid (0.1%, v/v) (pH 3, eluent A) and ammonium formate 
solution with acetonitrile:methanol (50:50, v/v) containing formic acid (0.1%, v/v) and water (1%, 
v/v) (eluent B). The flow rate was set to 500 µL/min for 10 min and 800 µL/min from 10-13.5 min 
and the gradient was programmed as follows: 0-1.0 min 1% B, 1-10 min to 99% B, 10-11.5 min 
hold 99% B, 11.5-13.5 min hold 1% B. The HESI-II source conditions were as described above, but 
with a scan range of m/z 130-1000.  
For DDA, High Energy Collisional Dissociation (HCD) experiments were performed on the 
five most intense precursor ions selected from FS using DDA (loop count 5). The five most intense 
precursor ions were transferred to an exclusion list for 8 s, defined by the term dynamic exclusion. 
The remaining settings for DDA mode were as follows: resolution, 17,500; microscans 1, AGC 
target, 2e5; maximum IT, 250 ms; isolation window, 1.0 m/z, HCD with stepped NCE, 17.5, 35, 
and 52.5%, spectrum data type, profile, and underfill ratio, 0.5%. 
For identification (I), the accurate precursor ion must be detectable and the underlying HR-
MS/MS spectrum must fit with the reference library spectrum. For Detection (D), only the accurate 
precursor ion must be detectable. This classification was in accordance to that described by 
Broecker et al. [29]. 
 
 
Results and discussion 
 
HR-MS/MS fragmentation and identification of 25I-NBOMe and its phase I metabolites 
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Thirty seven phase I metabolites could be identified. Therefore, besides the MS2 spectra of 25I-
NBOMe only those representing typical pathways are depicted in Fig. 1 and discussed in detail 
here. A list of all phase I metabolites is given in Table 1. The precursor masses (PM) are given with 
the calculated exact masses. The 4-iodo-2,5-dimethoxyphenethylamine partial structure of the 
parent compound will be referred as 2C part on the following pages. Fragmentation patterns will be 
discussed of representatives for each metabolic reactions leading to different fragmentation.  
25I-NBOMe (1 in Fig. 1 and Table 1; PM at m/z 428.0717, M+H) showed a fragmentation 
pattern, characteristic also for most of the detected metabolites. The most abundant fragment ion 
(FI) in MS2 at m/z 121.0653 represented the cleavage of the methoxybenzyl moiety, followed by the 
loss of the methoxy group (-30.0105 u) producing the tropylium ion at m/z 91.0548. The FI 
representing the 2C part showed a low abundance of less than 3 % (inserts of the corresponding 
spectra in Fig. 1). The FI at m/z 305.9991 representing the 2C iminium ion resulted from benzyl 
cleavage. A loss of NH (- 15.0109 u) formed the FI at m/z 290.9882 followed by a loss of a methyl 
radical (- 15.0235 u) of one of the two methoxy groups in the 2C part resulting in FI at m/z 
275.9647. The FI at m/z 301.1678 (C18H23O3N) resulted from a loss of iodine as a radical. One FI at 
m/z 272.1407 (C17H20O3) could not result from a cleavage of the unchanged parent compound (loss 
of CH3NI). In absence of other plausible explanations, a rearrangement reaction of the parent 
compound was postulated (Fig. 2). This rearrangement might be explained by an intramolecular 
electrophilic attack of the benzyl carbon at position 3, 4, or 6 of the 2C ring system, which was 
activated by the +M effects of the two methoxy groups and the iodine atom and by the +I effect of 
the alkyl chain. After elimination of HI and NH=CH2 this led to the FI at m/z 272.1407 (C17H20O3). 
The MS2 spectra of the N-demethoxybenzyl metabolite (2C-I, 5, PM at m/z 308.0148, M+H) 
showed a most abundant FI at m/z 290.9882 representing a shift of ammonia (- 17.0266 u). As 
described above, a loss of a methyl radical (-15.0235 u) formed the FI at m/z 275.9647. In the 
parent compound spectrum, the same fragments were found without the postulated rearrangement 
reaction. This metabolite could be further confirmed by comparison with reference material. 
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N-demethoxybenzylation in combination with O-demethylation led to two isomers of N-
demethoxybenzyl-O-demethyl 25I-NBOMe (2 and 3, PM at m/z 293.9991, M+H). Both showed 
more or less the same fragmentation pattern (m/z 261.9491 and 276.9726) and an exact prediction, 
which methoxy group was demethylated, cannot be done. This was marked by a tilde bond in the 
structures (Figs. 1-4). The fragmentation corresponds to the N-demethoxybenzyl metabolite (5) 
with a loss of one methyl group (- 15.0235 u). 
The spectra of O-demethyl metabolites (12 and 14) showed a PM at m/z 414.0561 (M+H) 
with the elemental composition of C17H21O3NI. The FIs at m/z 91.0548 and 121.0653 represented 
the unchanged methoxybenzyl moiety and indicated O-demethylation at the 2C part. The FIs at m/z 
276.9726 and 291.9835 corresponded to those of the parent compound with demethylation at one of 
the two methoxy groups (12). This metabolite showed FIs indicating the postulated rearrangement 
reaction as described for the parent compound. The FI at m/z 397.0301 (C17H18O3I) resulted from a 
loss of ammonia (- 17.0266 u) of the precursor, which could occur in the course of the postulated 
rearrangement reaction. Further products are the FIs at m/z 270.1256 and 287.1521 representing the 
rearrangement products of the de-iodinated precursor followed by elimination of ammonia. The 
other O-demethyl metabolite (14, PM at m/z 414.0561, M+H) showed different fragmentation 
patterns. The shift of the FI at m/z 121.0653 (12, unchanged methoxybenzyl moiety) to m/z 
107.0497 resulted from a loss of the methyl group of the methoxybenzyl moiety. In contrast to the 
parent compound, the 2C part showed a FI at m/z 308.0148 indicating a primary amine (as 
described for the N-demethoxybenzyl metabolite, 5) and not an iminium ion. The following 
fragmentation patterns were similar to those of the parent compound. The FIs of the 2C part were 
the same as already described for the N-demethoxybenzyl metabolite (5). The relative abundance of 
the 2C FIs was much higher than those seen for the parent compound spectra, which might be 
explained by a hydrogen bond between the resulting hydroxy group of the methoxybenzyl moiety 
and the nitrogen atom of the 2C part. This hydrogen bond might stabilize the molecule explaining 
why this metabolite did not show any FIs corresponding to the already described rearrangement 
reaction. Furthermore, this hydrogen bond led to another fragment of the 2C part compared to the 
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non O-demethylated methoxybenzyl moiety. Instead of the resulting iminium ion (1, m/z 305.9991), 
a primary amine was formed (m/z 308.0148). This fragmentation pattern could be seen for all 
metabolites with an O-demethylation at the methoxybenzyl moiety. 
Hydroxylation took place at different positions (32, 34, and 35; PM at m/z 444.0666, M+H). 
Isomer 1 (32) showed the fragments of the unchanged methoxybenzyl moiety (m/z 91.0548 and 
121.0653) indicating hydroxylation at the 2C part (m/z 306.9831). As no fragments for loss of water 
were observed, hydroxylation at the aryl ring system could be assumed. Isomer 4 (35) did also form 
FI at m/z 306.9831, but the FI at m/z 426.0561 representing loss of water (- 18.0100 u) indicated 
hydroxylation at the alkyl chain at an unknown position. Metabolic and/or artificial dehydration led 
to dehydro 25I-NBOMe (22, PM at m/z 426.0561, M+H; spectrum not shown). The most abundant 
FIs at m/z 91.0548 and 121.0653 represented the unchanged methoxybenzyl moiety, so the double 
bond might be located in the 2C part. The position of the double bond might be between the alpha 
carbon and the nitrogen forming an imine (25I-NBOMe imine analog [5]). The FIs of the 2C part 
were different. The FI at m/z 303.9835 representing the 2C nitrilium ion resulted from the benzyl 
cleavage. In contrast to the compound spectra this fragment did not show a loss of ammonia. The 
loss of iodine radical from the precursor led to the FI at m/z 299.1521. This metabolite did not show 
any FIs for the postulated rearrangement reaction. Finally, isomer 3 (34) showed a FI at m/z 
137.0603 resulting from a hydroxylation at the methoxybenzyl moiety and FIs at m/z 275.9647 and 
290.9882 representing the unchanged 2C part as described above. 
The fragmentation patterns of metabolites hydroxylated at the methoxybenzyl moiety and O-
demethylated at both parts (26 and 28; PM at m/z 430.0510, M+H) corresponded to the respective 
O-demethyl (12 and 14) or hydroxy (34) metabolite. Isomer 2 (26) showed FIs at m/z 137.0603 and 
276.9726 representing hydroxylation at the methoxybenzyl moiety and O-demethylation at the 2C 
part. The exact position of the hydroxylation and O-demethylation could not be predicted. Isomer 4 
(28) showed FIs of the unchanged 2C part (m/z 290.9882 and 308.0148). Metabolic O-
demethylation (- 14.0157 u) and hydroxylation (+ 15.9950 u) at the methoxybenzyl moiety (m/z 
121.0653) led to m/z 123.0446.  
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HR-MS/MS fragmentation and identification of the phase II metabolites  
 
Thirty phase II metabolites could be identified and selected spectra representing the various 
pathways are depicted in Fig. 3. A list of all phase II metabolites is given in Table 2. All 
glucuronides eliminated glucuronic acid (- 176.0321 u) and all sulfates sulfuric acid (- 79.9568 u). 
For example, the glucuronidated O-demethyl metabolite (58, PM at m/z 590.0882, M+H) eliminated 
glucuronic acid and thus, the rest of the spectrum corresponded to that of the O-demethyl 
metabolite (14, Fig. 1). Further fragments were formed of partial structures containing the 
glucuronic or sulfuric acid rests. These allowed elucidation at which part of the molecule 
conjugation took place. For the O,O-bis-demethyl metabolite (8, PM at m/z 400.0404, M+H, 
spectrum not shown), two different sulfation products (48 and 49, PM at m/z 479.9972, M+H) could 
be detected with different fragmentation patterns. In the spectrum of isomer 2 (48) the FIs at m/z 
356.9294 and 373.9556 represented sulfation at the 2C part. In contrast, isomer 3 (49) showed FI at 
m/z 204.0331 representing sulfation at the methoxybenzyl moiety. The spectrum of the 
glucuronidated O,O-bis-demethyl metabolite (54, PM at m/z 576.0725, M+H) showed a FI at m/z 
470.0312 representing glucuronidation at the 2C part. The glucuronide of the hydroxy metabolite 
isomer 3 (69, PM at m/z 620.0987, M+H) formed a FI at m/z 313.0923 confirming glucuronidation 
of the metabolite hydroxylated at the methoxybenzyl moiety. The glucuronide of the O,O-bis-
demethyl-hydroxy metabolite (60, PM at m/z 592.0674, M+H) showed a FI at m/z 299.0767 
representing glucuronidation of one of the hydroxy groups at the methoxybenzyl moiety.  
As already described for 2C-I [17], the two N-demethoxybenzyl-O-demethyl metabolites (2 
and 3) were conjugated with an acetyl group forming two isomers of N-demethoxybenzyl-O-
demethyl-N-acetyl-25I-NBOMe (39 and 40, PM at m/z 336.0091 M+H). In the following only 
isomer 1 (39) will be discussed. This conjugation reaction could be catalyzed by the N-acetyl-
transferase (NAT) [30]. The fragmentation pattern was similar to that of the unacetylated 
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metabolites, but FI at m/z 209.1052 resulted from a loss of iodine as a radical and FI at m/z 
336.0091 represented the N-acetylated 2C part with iodine. 
O,O-bis-demethylation at the 2C part (7) led to hydroquinone, which could be conjugated 
with glutathione (GSH) by the glutathione-S-transferase [31]. The corresponding degradation 
products of GSH [31] [31] O,O-bis-demethyl-S-methyl (41, PM at m/z 446.0281, M+H) and the 
O,O-bis-demethyl-acetylcysteine (51, PM at m/z 561.0551, M+H) metabolites could be detected. 
Both spectra showed FIs of the unchanged methoxybenzyl moiety (m/z 91.0548 and 121.0653). 
Both metabolites showed fragmentation patterns for the postulated rearrangement reaction. The S-
methyl metabolite (41) formed two FIs representing the rearranged O,O-bis-demethylated-S-
methylated (m/z 322.9603) and S-demethylated (m/z 307.9368) 2C part. The spectrum of the 
acetylcysteine conjugated metabolite (51) showed one FI at m/z 432.0130 representing the O,O-bis-
demethyl sulfide and one at m/z 455.0130 representing the rearranged 2C part conjugated with the 
intact N-acetylcysteine part. 
Another conjugation formed three different metabolites. In the following only one metabolite 
will be discussed in detail due to similar fragmentation characteristics. The bis-hydroxylation at the 
methoxybenzyl moiety (37 and 38) could form a catechol structure (vicinal bis-hydroxylation). 
These metabolites could be a substrate for the catechol-O-methyl-transferase (COMT). Products of 
this conjugation could be found. In detail, the bis-hydroxy-O-methyl metabolite (46, PM at m/z 
474.0772, M+H) showed the FI at m/z 167.0708 resulted from a shift of the FI at m/z 153.0552 by 
loss of one methyl group (+ 14.0156 u) representing the product of the COMT reaction. In addition, 
the FIs at m/z 290.9882 and 308.0148 represented the unchanged 2C part. The PM at m/z 474.0772 
could not be found in the MS2 spectra (marked with brackets in Fig. 3). The other two metabolites 
formed by the COMT were the O,O-bis-demethyl-bis-hydroxy-O-methyl metabolite (42, PM at 
446.0459, M+H) and the O-demethyl-bis-hydroxy-O-methyl metabolite (43, PM at m/z 460.0616, 
M+H, Table. 2). 
 
Proposed metabolic pathways  
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According to the metabolites identified in rat and human urine after cleavage of conjugates (Table 
1), the following metabolic pathways, depicted in Fig. 4, could be proposed: mono-demethylation 
(12, 13, and 14), bis-demethylation (7, 8, and 9), tris-demethylation (6) of the methoxy groups, 
mono- and bis-hydroxylation (32-36; 38), N-demethoxybenzylation (5), and combinations of mono-
hydroxylation with mono-demethylation (25-30), and bis-demethylation (15-21) as well as bis-
hydroxylation with mono-demethylation (37) and N-demethoxybenzylation with mono-
demethylation (2 and 3) followed by oxidative deamination and oxidation to the corresponding 
carboxylic acid (4).  
In summary, O-demethylation seemed to be the main metabolic pathway and N-
demethoxybenzylation only a minor one in humans and rats. However, the relative abundance of 
the different metabolites varied between the species, but it should also be kept in mind that the rat 
urines were pooled over 24 h and the human urine was collected at an unknown time after 
administration of an unknown dose. Finally, the relation of the metabolites may vary over the time 
of excretion. A further limitation is that the rough estimation of relative abundances was based on 
the assumption that all compounds would show similar peak areas in the applied LC-MS system if 
present in the same concentration. 
The following phase II metabolites could be proposed for humans and/or rats as given in Fig. 
4 and in Table 2: glucuronidation (G) and/or sulfation (S) of the O-demethyl metabolites (56G-
58G, and 50S), of the O,O-bis-demethyl metabolites (53G-55G and 47S-49S), of O,O,O-tris-
demethyl metabolite (52G, 44S, and 45S), of the O-demethyl-hydroxy metabolites (63G-67G), of 
the O,O-bis-demethyl-hydroxy metabolites (59G-62G), and of the hydroxy metabolites (68G and 
69G). Glutathione conjugation could be proposed for the O,O-bis-demethyl metabolite isomer 1 
(41GSH and 51GSH), N-acetylation for the N-demethoxybenzyl-O-demethyl metabolites (39AC 
and 40AC), and O-methylation for the bis-hydroxy metabolite (46ME), the O-demethyl-bis-
hydroxy metabolite (43ME), and the O,O-bis-demethyl-bis-hydroxy-O-methyl metabolite (42ME). 
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In summary, all phase II pathways could be proposed for both species with the exception of 
the N-acetylation, which was observed only in rats after the high dose. Again, the relative 
abundance also of the different conjugates varied between the species, but this was only a rough 
estimation as already discussed above. 
 
CYP Initial Screening 
 
For identification of the CPYs catalyzing the initial metabolic steps, the ten most abundant human 
hepatic CYPs were incubated under conditions allowing a statement on the general involvement of 
a particular CYP enzyme. As summarized in Table 3, CYP2C9 and CYP2C19 were mainly 
involved in O-demethylation, CYP1A2 and CYP3A4 in hydroxylation, and CYP3A4 in N-
demethoxybenzylation. However, not all isomers detected in urine could be found in these 
incubations, e.g. only one metabolite O-demethylated at the 2C part.  
 
Toxicological detection of 25I-NBOMe by GC-MS SUSA 
 
Unfortunately, 25I-NBOMe and/or its metabolites could not be detected in rat urine after a common 
single dose reported in trip reports (https://www.erowid.org) and scaled by dose-by-factor approach 
from man to rat according to Sharma and McNeill [32]. The authentic human urine sample was also 
negative. This could be caused by lower sensitivity of GC-MS and most probably by the sample 
preparation. Preliminary studies showed that the NBOMe’s degraded in part during hydrolysis and 
exposure to oxygen. Only after the high dose, enzymatic cleavage of conjugates, solid-phase 
extraction, and acetylation according to Welter et al. [25], small amounts of 25I-NBOMe O-
demethyl metabolites could be detected. 
 
Toxicological detection of 25I-NBOMe by LC-MSn SUSA 
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The LC-MSn approach was able to detect 25I-NBOMe and/or its metabolites in rat urine after the 
0.05 or 0.1 mg/kg BW dose as well as in the authentic human urine sample. A list of the detected 
metabolites is given in Table 4. As already mentioned above, the differences of detected analytes in 
the human and rat urine samples could be caused by different doses and urine collection times.  
 
Toxicological detection of 25I-NBOMe by LC-HR-MS/MS SUSA 
 
In addition, the detectability was also tested by the new LC-HR-MS/MS screening approach (Helfer 
et al., submitted). As expected, this approach was also able to detect 25I-NBOMe and/or its 
metabolites in rat urine after the 0.05 or 0.1 mg/kg BW dose as well as in the authentic human urine 
sample. A list of the identified or detected metabolites in human as well as in rat samples is given in 
Table 5. Again, the differences of detected analytes in the human and rat urine samples could be 
caused by different doses and urine collection times. Figure 5 shows reconstituted ion 
chromatograms of the human urine sample indicating various metabolites, which could be 
identified according to definition given above. In this sample, the parent drug could only be 
detected in contrast to the rat urine samples after the 0.1 mg/kg BW dose. 
 
 
Conclusion 
 
25I-NBOMe was extensively metabolized with O-demethylation, O,O-bis-demethylation, and 
hydroxylations as predominant pathways. Several CYP isoenzymes were involved in formation of 
the main metabolites. An intake could be detected mainly via its metabolites by low and high 
resolution LC-MS SUSAs.  
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Table 1 List of 25I-NBOMe and its phase I metabolites detected in human (H) or rat (R) urine 
together with the masses of their precursor mass (PM) recorded in MS1, the corresponding 
characteristic fragment ions (FI) in MS2, the calculated exact masses, the corresponding elemental 
composition, the deviation of the measured from the calculated masses, given as errors in ppm, and 
the retention times (RT) in min. The metabolites were sorted by mass and RT.  
No. Metabolites and characteristic ions 
Measured accurate masses, u 
 
Relative intensity 
in MS2, % 
Calculated exact 
masses, m/z 
Elemental 
composition 
Error, ppm 
 
RT, min 
 
1 25I-NBOMe (H/R) 
 
    9.21 
MS1 PM at m/z 428.0720 (M+H) 13 428.0717 C18H23O3NI 0.65 
MS2 FI at m/z 91.0547 
FI at m/z 121.0650 
FI at m/z 272.1408 
FI at m/z 290.9878 
FI at m/z 305.9996 
 
48 
100 
3 
1 
0.5 
91.0548 
121.0653 
272.1412 
290.9882 
305.9991 
C7H7 
C8H9O 
C17H20O3 
C10H12O2I 
C10H13O2NI 
-0.82 
-2.81 
-1.64 
-1.40 
1.61 
2 25I-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 1 (H/R) 
 
4.89 
MS1 PM at m/z 293.9983 (M+H) 4 293.9991 C9H13O2NI -2.74 
MS2 FI at m/z 135.0440 
FI at m/z 150.0674 
FI at m/z 261.9486 
FI at m/z276.9716 
 
61 
56 
27 
100 
135.0446 
150.0681 
261.9491 
276.9726 
 
C8H7O2 
C9H10O2 
C8H7O2I 
C9H10O2I 
 
-4.48 
-4.53 
-1.84 
-3.46 
3 25I-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 2 (H/R) 
 
4.98 
MS1 PM at m/z 293.9983 (M+H) 6 293.9991 C9H13O2NI -2.74 
MS2 FI at m/z 135.0441 
FI at m/z 150.0676 
FI at m/z 261.9486 
FI at m/z 276.9719 
 
29 
31 
71 
100 
135.0446 
150.0681 
261.9491 
276.9726 
 
C8H7O2 
C9H10O2 
C8H7O2I  
C9H10O2I 
 
-3.74 
-3.20 
-1.84 
-2.37 
4 25I-NBOMe-M (N-demethoxybenzyl-O-demethyl-deamino-HOOC-) (H/R) 
 
7.24 
MS1 PM at m/z 306.9467 (M-H) 3 306.9467 C9H8O4I 0 
MS2 FI at m/z 126.9039 
FI at m/z 247.9337 
FI at m/z 262.9574 
 
100 
14 
6 
126.9045 
247.9334 
262.9569 
I 
C7H5O2I 
C8H8O2I 
-4.55 
1.08 
1.87 
5 25I-NBOMe-M (N-demethoxybenzyl-) (H/R) 
 
6.36 
MS1 PM at m/z 308.0147 (M+H) 4 308.0148 C10H15O2NI -0.18 
MS2 FI at m/z 149.0597 
FI at m/z 260.9404 
FI at m/z 275.9639 
FI at m/z 290.9872 
 
22 
36 
88 
100 
149.0603 
260.9413 
275.9647 
290.9882 
 
C9H9O2 
C8H6O2I 
C9H9O2I 
C10H12O2I 
 
-3.72 
-3.28 
-3.01 
-3.46 
6 25I-NBOMe-M (O,O,O-tris-demethyl-) (H/R) 
 
5.76 
MS1 PM at m/z 386.0243 (M+H) 15 386.0248 C15H17O3NI -1.22 
MS2 FI at m/z 107.0494 
FI at m/z 136.0519 
FI at m/z 262.9563 
FI at m/z 279.9827 
 
100 
36 
77 
36 
 
107.0497 
136.0524 
262.9569 
279.9835 
 
C7H7O 
C8H8O2 
C8H8O2I 
C8H11O2NI 
 
-2.71 
-3.90 
-2.31 
-2.70 
 
7 25I-NBOMe-M (O,O-bis-demethyl-) isomer1 (H/R) 
 
6.61 
MS1 PM at m/z 400.0405 (M+H) 8 400.0404 C16H19O3NI 0.19 
MS2 FI at m/z 91.0547 
FI at m/z 121.0649 
FI at m/z 256.1098 
FI at m/z 274.9562 
 
44 
100 
1 
1 
91.0548 
121.0653 
256.1099 
274.9569 
C7H7 
C8H9O 
C16C16O3 
C9H8O2I 
-0.82 
-3.63 
-0.57 
-2.57 
8 25I-NBOMe-M (O,O-bis-demethyl-) isomer 2 (H/R) 7.37 
Page 23 of 43 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
24 
 
 
MS1 PM at m/z 400.0400 (M+H) 13 400.0404 C16H19O3NI -1.06 
MS2 FI at m/z 107.0495 
FI at m/z 261.9487 
FI at m/z 276.9718 
FI at m/z 293.9984 
 
100 
13 
80 
30 
107.0497 
261.9491 
276.9726 
293.9991 
C7H7O 
C8H7O2I 
C9H10O2I 
C9H13O2NI 
-1.77 
-1.46 
-2.73 
-2.40 
9 25I-NBOMe-M (O,O-bis-demethyl-) isomer 3 (H/R) 
 
7.51 
MS1 PM at m/z 400.0405 (M+H) 17 400.0404 C16H19O3NI 0.19 
MS2 FI at m/z 107.0495 
FI at m/z 261.9487 
FI at m/z 276.9718 
FI at m/z 293.9983 
 
100 
29 
83 
33 
107.0497 
261.9491 
276.9726 
293.9991 
C7H7O 
C8H7O2I 
C9H10O2I 
C9H13O2NI 
-1.77 
-1.46 
-2.73 
-2.74 
10 25I-NBOMe-M (O-demethyl-dehydro-) isomer1 (H/R) 
 
7.19 
MS1 PM at m/z 412.0402 (M+H) 33 412.0404 C17H19O3NI -0.54 
MS2 FI at m/z 107.0494 
FI at m/z 179.0939 
FI at m/z 276.9715 
FI at m/z 305.9979 
 
100 
13 
15 
66 
107.0497 
179.0946 
276.9726 
305.9991 
C7H7O 
C10H13O2N 
C9H10O2I 
C10H13O2NI 
-2.71 
-4.07 
-3.82 
-3.94 
11 25I-NBOMe-M (O-demethyl-dehydro-) isomer2 (H/R) 
 
7.83 
MS1 PM at m/z 412.0401 (M+H) 5 412.0404 C17H19O3NI -0.78 
MS2 FI at m/z 91.0547 
FI at m/z 121.0650 
FI at m/z 285.1356 
FI at m/z 290.9748 
 
46 
100 
16 
19 
91.0548 
121.0653 
285.1365 
290.9756 
C7H7 
C8H9O 
C17H19O3N 
C9H10O2NI 
-0.82 
-2.81 
-3.14 
-2.86 
12 25I-NBOMe-M (O-demethyl-) isomer 1 (H/R) 
 
8.08 
MS1 PM at m/z 414.0552 (M+H) 6 414.0561 C17H21O3NI -2.11 
MS2 FI at m/z 91.0546 
FI at m/z 121.0649 
FI at m/z 270.1252 
FI at m/z 287.1509 
FI at m/z 397.0288 
 
48 
100 
2 
1 
1 
91.0548 
121.0653 
270.1256 
287.1521 
397.0301 
C7H7 
C8H9O 
C17H18O3 
C17H21O3N 
C17H18O3I 
 
-1.92 
-3.63 
-1.46 
-4.33 
-3.20 
13 25I-NBOMe-M (O-demethyl-) isomer 2 (H/R) 
 
8.25 
MS1 PM at m/z 414.0561 (M+H) 10 414.0561 C17H21O3NI 0 
MS2 FI at m/z 91.0547 
FI at m/z 121.0650 
FI at m/z 258.1256 
FI at m/z 270.1259 
 
50 
100 
1 
0.4 
91.0548 
121.0653 
258.1256 
270.1256 
C7H7 
C8H9O 
C16H18O3 
C17H18O3N 
-0.82 
-2.81 
0 
1.13 
14 25I-NBOMe-M (O-demethyl-) isomer 3 (H/R) 
 
8.51 
MS1 PM at m/z 414.0561 (M+H) 10 414.0561 C17H21O3NI 0 
MS2 FI at m/z 107.0494 
FI at m/z 275.9639 
FI at m/z 290.9872 
FI at m/z 308.0136 
 
100 
44 
79 
30 
107.0497 
275.9647 
290.9882 
308.0148 
C7H7O 
C9H9O2I 
C10H12O2I 
C10H15O2NI 
-2.71 
-3.01 
-3.46 
-3.75 
15 25I-NBOMe-M (O,O-bis-demethyl-HO-) isomer 1 (H/R) 
 
5.77 
MS1 PM at m/z 416.0355 (M+H) 8 416.0353 C16H19O4NI 0.39 
MS2 FI at m/z 107.0495 
FI at m/z 137.0598 
FI at m/z 272.1039 
FI at m/z 399.0078 
 
38 
100 
1 
1 
107.0497 
137.0603 
272.1049 
399.0093 
C7H7O 
C8H9O2I 
C16H16O4 
C16H16O4I 
-1.77 
-3.32 
-3.53 
-3.85 
16 25I-NBOMe-M (O,O-bis-demethyl-HO-) isomer 2 (H/R) 
 
6.24 
MS1 PM at m/z 416.0355 (M+H) 12 416.0353 C16H19O4NI 0.39 
MS2 FI at m/z 123.0443 
FI at m/z 150.0677 
FI at m/z 276.9720 
FI at m/z 293.9984 
 
100 
31 
90 
32 
123.0446 
150.0681 
276.9726 
293.9991 
C7H7O2 
C9H10O2 
C9H10O2I 
C9H13O2NI 
-2.48 
-2.53 
-2.01 
-2.40 
17 25I-NBOMe-M (O,O-bis-demethyl-HO-) isomer 3 (H/R) 
 
6.31 
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MS1 PM at m/z 416.0355 (M+H) 15 416.0353 C16H19O4NI 0.39 
MS2 FI at m/z 123.0442 
FI at m/z 150.0677 
FI at m/z 276.9717 
FI at m/z 293.9984 
 
100 
29 
94 
32 
123.0446 
150.0681 
276.9726 
293.9991 
C7H7O2 
C9H10O2 
C9H10O2I 
C9H13O2NI 
-3.29 
-2.53 
-2.01 
-2.40 
18 25I-NBOMe-M (O,O-bis-demethyl-HO-) isomer 4 (H) 
 
6.50 
MS1 PM at m/z 416.0355 (M+H) 15 416.0353 C16H19O4NI 0.39 
MS2 FI at m/z 107.0496 
FI at m/z 277.9436 
FI at m/z 292.9670 
FI at m/z 309.9932 
 
100 
66 
75 
33 
107.0497 
277.9440 
292.9675 
309.9940 
C7H7O 
C8H7O3I 
C9H10O3I 
C9H13O3NI 
-0.84 
-1.43 
-1.61 
-2.65 
19 25I-NBOMe-M (O,O-bis-demethyl-HO-) isomer 5 (H/R) 
 
6.78 
MS1 PM at m/z 416.0351 (M+H) 17 416.0353 C16H19O4NI -0.57 
MS2 FI at m/z 123.0442 
FI at m/z 150.0675 
FI at m/z 276.9716 
FI at m/z 293.9984 
 
100 
19 
66 
24 
123.0446 
150.0681 
276.9726 
293.9991 
C7H7O2 
C9H10O2 
C9H10O2I 
C9H13O2NI 
-3.29 
-3.86 
-3.46 
-2.40 
20 25I-NBOMe-M (O,O-bis-demethyl-HO-) isomer 6 (H/R) 
 
6.94 
MS1 PM at m/z 416.0350 (M+H) 20 416.0353 C16H19O4NI -0.81 
MS2 FI at m/z 123.0441 
FI at m/z 150.0674 
FI at m/z 276.9717 
FI at m/z 293.9983 
 
100 
13 
71 
24 
123.0446 
150.0681 
276.9726 
293.9991 
C7H7O2 
C9H10O2 
C9H10O2I 
C9H13O2NI 
-4.10 
-4.53 
-3.09 
-2.74 
21 25I-NBOMe-M (O,O-bis-demethyl-HO-) isomer 7 (R) 
 
7.26 
MS1 PM at m/z 416.0325 (M+H) 11 416.0353 C16H19O4NI -6.82 
MS2 FI at m/z 107.0495 
FI at m/z 165.0785 
FI at m/z 291.9827 
FI at m/z 398.0244 
 
90 
52 
100 
14 
107.0497 
165.0790 
291.9835 
398.0253 
C7H7O 
C9H11O2N 
C9H11O2NI 
C16H17O3NI 
-1.77 
-2.90 
-2.59 
-2.31 
22 25I-NBOMe-M (dehydro-) (H/R) 
 
7.89 
MS1 PM at m/z 426.0559 (M+H) 25 426.0561 C18H21O3NI -0.41 
MS2 FI at m/z 91.0547 
FI at m/z 121.0650 
FI at m/z 287.9514 
FI at m/z 303.9824 
 
47 
100 
1 
8 
91.0548 
121.0653 
287.9522 
303.9835 
C7H7 
C8H9O 
C9H7O2NI 
C10H11O2NI 
-0.82 
-2.81 
-2.63 
-3.47 
23 25I-NBOMe-M (O-demethyl-dehydro-HO-) isomer 1 (H/R) 
 
6.07 
MS1 PM at m/z 428.0348 (M+H) 30 428.0353 C17H19O4NI -1.26 
MS2 FI at m/z 123.0442 
FI at m/z 179.0940 
FI at m/z 276.9715 
FI at m/z 305.9984 
 
100 
14 
18 
83 
123.0446 
179.0946 
276.9726 
305.9991 
C7H7O2 
C10H13O2N 
C9H10O2I 
C10H13O2NI 
-3.29 
-3.51 
-3.82 
-2.31 
24 25I-NBOMe-M (O-demethyl-dehydro-HO-) isomer 2 (R) 
 
6.26 
MS1 PM at m/z 428.0348 (M+H) 33 428.0353 C17H19O4NI -1.26 
MS2 FI at m/z 107.0494 
FI at m/z 178.0625 
FI at m/z 292.9666 
FI at m/z 321.9927 
 
100 
23 
8 
54 
107.0497 
178.0630 
292.9675 
321.9940 
C7H7O 
C10H10O3 
C9H10O3I 
C10H13O3NI 
-2.71 
-2.78 
-2.98 
-4.10 
25 25I-NBOMe-M (O-demethyl-HO-) isomer 1 (H) 
 
7.15 
MS1 PM at m/z 430.0515 (M+H) 12 430.0510 C17H21O4NI 1.19 
MS2 FI at m/z 109.0651 
FI at m/z 137.0598 
FI at m/z 276.9716 
FI at m/z 293.9983 
100 
67 
18 
7 
109.0653 
137.0603 
276.9726 
293.9991 
C7H9O 
C8H9O2 
C9H10O2I 
C9H13O2NI 
-2.20 
-3.32 
-3.46 
-2.74 
26 25I-NBOMe-M (O-demethyl-HO-) isomer 2 (H/R) 
 
7.24 
MS1 PM at m/z 430.0515 (M+H) 6 430.0510 C17H21O4NI 1.19 
MS2 FI at m/z 107.0495 
FI at m/z 137.0598 
44 
100 
107.0497 
137.0603 
C7H7O 
C8H9O2 
-1.77 
-3.32 
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26 
 
FI at m/z 286.1198 
FI at m/z 303.1472 
 
2 
1 
286.1205 
303.1471 
C17H18O4 
C17H21O4N 
-2.48 
0.47 
27 25I-NBOMe-M (O-demethyl-HO-) isomer 3 (H/R) 
 
7.35 
MS1 PM at m/z 430.0511 (M+H) 11 430.0510 C17H21O4NI 0.26 
MS2 FI at m/z 107.0495 
FI at m/z 137.0598 
FI at m/z 276.9726 
FI at m/z 286.1212 
 
40 
100 
1 
1 
107.0497 
137.0603 
276.9726 
286.1205 
C7H7O 
C8H9O2 
C9H10O2I 
C17H18O4 
-1.77 
-3.32 
0 
2.41 
28 25I-NBOMe-M (O-demethyl-HO-) isomer 4 (H) 
 
7.36 
MS1 PM at m/z 430.0511 (M+H) 13 430.0510 C17H21O4NI 0.26 
MS2 FI at m/z 123.0442 
FI at m/z 275.9641 
FI at m/z 290.9874 
FI at m/z 308.0137 
 
100 
49 
95 
32 
123.0446 
275.9647 
290.9882 
308.0148 
C7H7O2 
C9H9O2I 
C10H12O2I 
C10H15O2NI 
-3.29 
-2.29 
-2.77 
-3.43 
29 25I-NBOMe-M (O-demethyl-HO-) isomer 5 (H) 
 
7.92 
MS1 PM at m/z 430.0509 (M+H) 8 430.0510 C17H21O4NI -0.20 
MS2 FI at m/z 123.0442 
FI at m/z 275.9641 
FI at m/z 290.9873 
FI at m/z 308.0137 
 
100 
40 
70 
21 
123.0446 
275.9647 
290.9882 
308.0148 
C7H7O2 
C9H9O2I 
C10H12O2I 
C10H15O2NI 
-3.29 
-2.29 
-3.12 
-3.43 
30 25I-NBOMe-M (O-demethyl-HO-) isomer 6 (H) 
 
7.95 
MS1 PM at m/z 430.0509 (M+H) 6 430.0510 C17H21O4NI -0.20 
MS2 FI at m/z 91.0547 
FI at m/z 121.0650 
FI at m/z 291.9825 
FI at m/z 412.0403 
 
47 
100 
3 
8 
91.0548 
121.0653 
291.9835 
412.0410 
C7H7 
C8H9O 
C9H11O2NI 
C17H19O3NI 
-0.82 
-2.81 
-3.27 
-1.63 
31 25I-NBOMe-M (dehydro-HO-) (H/R) 
 
7.09 
MS1 PM at m/z 442.0507 (M+H) 21 442.0510 C18H21O4NI -0.65 
MS2 FI at m/z 91.0547 
FI at m/z 121.0650 
FI at m/z 304.9539 
FI at m/z 319.9775 
 
53 
100 
2 
6 
91.0548 
121.0653 
304.9549 
319.9784 
C7H7 
C8H9O 
C9H8O3NI 
C10H11O3NI 
-0.82 
-2.81 
-3.27 
-2.72 
32 25I-NBOMe-M (HO-) isomer 1 (R) 
 
7.72 
MS1 PM at m/z 444.0668 (M+H) 16 444.0666 C18H23O4NI 0.37 
MS2 FI at m/z 91.0547 
FI at m/z 121.0650 
FI at m/z 276.9361 
FI at m/z 306.9822 
 
51 
100 
2 
7 
91.0548 
121.0653 
276.9362 
306.9831 
C7H7 
C8H9O 
C8H6O3I 
C10H12O3I 
-0.82 
-2.81 
-0.26 
-3.00 
33 25I-NBOMe-M (HO-) isomer 2 (H) 
 
8.24 
MS1 PM at m/z 444.0668 (M+H) 16 444.0666 C18H23O4NI 0.37 
MS2 FI at m/z 109.0651 
FI at m/z 137.0597 
FI at m/z 290.9872 
FI at m/z 308.0135 
 
100 
78 
32 
12 
109.0653 
137.0603 
290.9882 
308.0148 
C7H9O 
C8H9O2 
C10H12O2I 
C10H15O2NI 
-2.20 
-4.05 
-3.46 
-4.08 
34 25I-NBOMe-M (HO-) isomer 3 (H/R) 
 
8.34 
MS1 PM at m/z444.0667 (M+H) 9 444.0666 C18H23O4NI 0.14 
MS2 FI at m/z 107.0494 
FI at m/z 137.0598 
FI at m/z 288.1353 
FI at m/z 290.9872 
 
43 
100 
2 
1 
107.0497 
137.0603 
288.1362 
290.9882 
C7H7O 
C8H9O2 
C17H20O4 
C10H12O2I 
-2.71 
-3.32 
-2.98 
-3.46 
35 25I-NBOMe-M (HO-) isomer 4 (H) 
 
8.81 
MS1 PM at m/z 444.0675 (M+H) 10 444.0666 C18H23O4NI 1.94 
MS2 FI at m/z 91.0547 
FI at m/z 121.0651 
FI at m/z 291.1589 
FI at m/z 426.0553 
53 
100 
4 
3 
91.0548 
121.0653 
291.1596 
426.0561 
C7H7 
C8H9O 
C17H23O4 
C18H21O3NI 
-0.82 
-1.98 
-2.52 
-1.81 
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27 
 
 
36 25I-NBOMe-M (HO-) isomer 5 (H) 
 
8.91 
MS1 PM at m/z 444.0650 (M+H) 7 444.0666 C18H23O4NI -3.69 
MS2 FI at m/z 137.0598 
FI at m/z 275.9641 
FI at m/z 290.9873 
FI at m/z 308.0139 
 
100 
39 
83 
41 
137.0603 
275.9647 
290.9882 
308.0148 
C8H9O2 
C9H9O2I 
C10H12O2I 
C10H15O2NI 
-3.32 
-2.29 
-3.12 
-2.78 
37 25I-NBOMe-M (O-demethyl-bis-HO-) (H/R) 
 
6.79 
MS1 PM at m/z 446.0464 (M+H) 1 446.0459 C17H21O5NI 1.12 
MS2 FI at m/z 153.0545 
FI at m/z 261.9484 
FI at m/z 276.9717 
FI at m/z 293.9982 
 
100 
27 
95 
35 
153.0552 
261.9491 
276.9726 
293.9991 
C8H9O3 
C8H7O2I 
C9H10O2I 
C9H13O2NI 
-4.38 
-2.60 
-3.09 
-3.08 
38 25I-NBOMe-M (bis-HO-) (H) 
 
7.39 
MS1 PM at m/z 460.0616 (M+H) 1 460.0616 C18H23O5NI 0 
MS2 FI at m/z 153.0550 
FI at m/z 290.9885 
FI at m/z 308.0142 
FI at m/z 442.0516 
 
88 
100 
37 
8 
153.0552 
290.9882 
308.0148 
442.0515 
C8H9O3 
C10H12O2I 
C10H15O2NI 
C18H21O4NI 
-1.11 
1.01 
-1.81 
0.14 
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Table 2 List of all phase II metabolites detected in human (H) or rat (R) urine together with the 
masses of their precursor mass (PM) recorded in MS1, the corresponding characteristic fragment 
ions (FI) in MS2, the calculated exact masses, the corresponding elemental composition, the 
deviation of the measured from the calculated masses, given as errors in ppm, and the retention 
times (RT) in min. The metabolites were sorted by mass and RT. 
No. Metabolites and characteristic ions 
Measured accurate masses, u 
 
Relative intensity 
in MS2, % 
Calculated exact 
masses, u 
Elemental 
composition 
Error, ppm RT, min 
 
39 25I-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 1 (R) 
 
7.43 
MS1 PM at m/z 336.0075 (M+H) 16 336.0091 C11H15O3NI -4.83 
MS2 FI at m/z 150.0678 
FI at m/z 209.1049 
FI at m/z 261.9489 
FI at m/z 276.9724 
FI at m/z 293.9987 
 
88 
27 
20 
100 
20 
150.0681 
209.1052 
261.9491 
276.9726 
293.9991 
C9H10O2 
C11H15O3N 
C8H7O2I 
C9H10O2I 
C9H13O2NI 
-1.87 
-1.41 
-0.69 
-0.57 
-1.38 
40 25I-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 2 (R) 
 
7.72 
MS1 PM at m/z 336.0086 (M+H) 23 336.0091 C11H15O3NI -1.56 
MS2 FI at m/z 150.0677 
FI at m/z 209.1048 
FI at m/z 261.9488 
FI at m/z 276.9723 
FI at m/z 293.9987 
 
42 
17 
51 
100 
24 
 
150.0681 
209.1052 
261.9491 
276.9726 
293.9991 
C9H10O2 
C11H15O3N 
C8H7O2I 
C9H10O2I 
C9H13O2NI 
-2.53 
-1.88 
-1.08 
-0.93 
-1.38 
41 25I-NBOMe-M (O,O-bis-demethyl-) S-methyl (H/R) 
 
8.18 
MS1 PM at m/z 446.0278 (M+H) 11 446.0281 C17H21O3NIS -0.77 
MS2 FI at m/z 121.0650 
FI at m/z 302.0973 
FI at m/z 307.9358 
FI at m/z 322.9592 
 
100 
1 
4 
4 
121.0653 
302.0977 
307.9368 
322.9603 
C8H9O 
C17H18O3S 
C9H9O2IS 
C10H12O2IS 
-2.81 
-1.21 
-3.26 
-3.34 
42 25I-NBOMe-M (O,O-bis-demethyl-bis-HO-) O-methyl (H/R) 
 
7.72 
MS1 PM at m/z 446.0473 (M+H) 9 446.0459 C17H21O5NI 3.13 
MS2 FI at m/z 137.0599 
FI at m/z 167.0703 
FI at m/z 262.9564 
 
32 
100 
33 
 
137.0603 
167.0708 
262.9569 
C8H9O2 
C9H11O3 
C8H8O2I 
-2.59 
-3.11 
-1.93 
 
43 25I-NBOMe-M (O-demethyl-bis-HO-) O-methyl (H/R) 
 
7.01 
MS1 PM at m/z 460.0624 (M+H) 0 460.0616 C18H23O5NI 1.84 
MS2 FI at m/z 137.0600 
FI at m/z 167.0707 
FI at m/z 276.9730 
FI at m/z 293.9990 
 
32 
100 
8 
4 
137.0603 
167.0708 
276.9726 
293.9991 
C8H9O2 
C9H11O3 
C9H10O2I 
C9H13O2NI 
-1.86 
-0.72 
1.60 
-0.36 
 
44 25I-NBOMe-M (O,O,O-tris-demethyl-) sulfate isomer 1 (R) 
 
5.79 
MS1 PM at m/z 465.9823 (M+H) 21 465.9816 C15H17O6NIS 1.52 
MS2 FI at m/z 107.0496 
FI at m/z 262.9567 
FI at m/z 342.9129 
FI at m/z 359.9395 
FI at m/z 386.0250 
 
100 
71 
35 
83 
11 
 
107.0497 
262.9569 
342.9137 
359.9403 
386.0253 
C7H7O 
C8H8O2I 
C8H8O5IS 
C8H11O5NIS 
C15H17O3NI 
-0.84 
-0.79 
-2.40 
-2.15 
-0.83 
45 25I-NBOMe-M (O,O,O-tris-demethyl-) sulfate isomer 2 (R) 
 
6.14 
MS1 PM at m/z 465.9825 (M+H) 27 465.9816 C15H17O6NIS 1.95 
MS2 FI at m/z 107.0496 
FI at m/z 262.9567 
FI at m/z 342.9132 
FI at m/z 359.9396 
100 
74 
27 
64 
107.0497 
262.9569 
342.9137 
359.9403 
C7H7O 
C8H8O2I 
C8H8O5IS 
C8H11O5NIS 
-0.84 
-0.79 
-1.53 
-1.87 
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FI at m/z 386.0250 
 
18 386.0253 C15H17O3NI -0.83 
46 25I-NBOMe-M (bis-HO-) O-methyl (H) 
 
8.05 
MS1 PM at m/z 474.0781 (M+H) 0 474.0772 C19H25O5NI 1.89 
MS2 FI at m/z 137.0600 
FI at m/z 167.0705 
FI at m/z 290.9881 
FI at m/z 308.0146 
 
31 
100 
18 
8 
137.0603 
167.0708 
290.9882 
308.0148 
C8H9O2 
C9H11O3 
C10H12O2I 
C10H15O2NI 
-1.86 
-1.92 
-0.37 
-0.51 
 
47 25I-NBOMe-M (O,O-bis-demethyl-) sulfate isomer 1 (H/R) 
 
6.54 
MS1 PM at m/z479.9982 (M+H) 7 479.9972 C16H19O6NIS 2.00 
MS2 FI at m/z 91.0549 
FI at m/z 121.0653 
FI at m/z 400.0409 
 
27 
100 
5 
91.0548 
121.0653 
400.0410 
C7H7 
C8H9O 
C16H19O3NI 
1.37 
-0.33 
-0.18 
48 25I-NBOMe-M (O,O-bis-demethyl-) sulfate isomer 2 (H/R) 
 
7.43 
MS1 PM at m/z 479.9978 (M+H) 24 479.9972 C16H19O6NIS 1.17 
MS2 FI at m/z 107.0496 
FI at m/z 276.9725 
FI at m/z 356.9288 
FI at m/z 373.9556 
FI at m/z 400.0407 
 
100 
84 
45 
84 
12 
107.0497 
276.9726 
356.9294 
373.9559 
400.0410 
C7H7O 
C9H10O2I 
C9H10O5IS 
C9H13O5NIS 
C16H19O3NI 
-0.84 
-0.21 
-1.61 
-0.86 
-0.68 
49 25I-NBOMe-M (O,O-bis-demethyl-) sulfate isomer 3 (R) 
 
7.99 
MS1 PM at m/z 479.9977 (M+H) 27 479.9972 C16H19O6NIS 0.96 
MS2 FI at m/z 107.0496 
FI at m/z 204.0331 
FI at m/z 276.9725 
FI at m/z 293.9987 
FI at m/z 400.0407 
 
87 
4 
100 
34 
71 
107.0497 
204.0331 
276.9726 
293.9991 
400.0410 
C7H7O 
C7H10O4NS 
C9H10O2I 
C9H13O2NI 
C16H19O3NI 
-0.84 
0 
-0.21 
-1.38 
-0.68 
50 25I-NBOMe-M (O-demethyl-) sulfate (H) 
 
8.12 
MS1 PM at m/z 494.0138 (M+H) 6 494.0129 C17H21O6NIS 1.84 
MS2 FI at m/z 91.0549 
FI at m/z 121.0652 
FI at m/z 397.0300 
FI at m/z 414.0568 
 
28 
100 
1 
8 
91.0548 
121.0653 
397.0301 
414.0566 
C7H7 
C8H9O 
C17H18O3I 
C17H21O3NI 
1.37 
-1.16 
-0.18 
0.43 
51 25I-NBOMe-M (O,O-bis-demethyl-) acetylcysteine (R) 
 
6.77 
MS1 PM at m/z 561.0544 (M+H) 22 561.0551 C21H26O6N2IS -1.23 
MS2 FI at m/z 121.0650 
FI at m/z 288.0818 
FI at m/z 432.0126 
FI at m/z 455.0129 
 
100 
1 
7 
2 
121.0653 
288.0820 
432.0130 
455.0138 
C8H9O 
C16H16O3S 
C16H19O3NIS 
C14H20O5N2IS 
-2.81 
-0.75 
-1.03 
-1.92 
52 25I-NBOMe-M (O,O,O-tris-demethyl-) glucuronide (R) 
 
4.62 
MS1 PM at m/z 562.0571 (M+H) 47 562.0569 C21H25O9NI 0.42 
MS2 FI at m/z 107.0496 
FI at m/z 262.9567 
FI at m/z 386.0250 
FI at m/z 456.0158 
 
68 
100 
48 
30 
107.0497 
262.9569 
386.0253 
456.0155 
C7H7O 
C8H8O2I 
C15H17O3NI 
C14H19O8NI 
-0.84 
-0.79 
-0.83 
0.56 
53 25I-NBOMe-M (O,O-bis-demethyl-) glucuronide isomer 1 (H/R) 
 
5.35 
MS1 PM at m/z 576.0731 (M+H) 35 576.0725 C22H27O9NI 1.02 
MS2 FI at m/z 91.0549 
FI at m/z 121.0653 
FI at m/z 400.0408 
 
30 
100 
25 
91.0548 
121.0653 
400.0410 
C7H7 
C8H9O 
C16H19O3NI 
1.37 
-0.33 
-0.43 
54 25I-NBOMe-M (O,O-bis-demethyl-) glucuronide isomer 2 (H/R) 
 
6.42 
MS1 PM at m/z 576.0733 (M+H) 46 576.0725 C22H27O9NI 1.37 
MS2 FI at m/z 107.0496 
FI at m/z 276.9724 
FI at m/z 293.9987 
FI at m/z 400.0410 
FI at m/z 470.0311 
60 
100 
42 
56 
22 
107.0497 
276.9726 
293.9991 
400.0410 
470.0312 
C7H7O 
C9H10O2I 
C9H13O2NI 
C16H19O3NI 
C15H21O8NI 
-0.84 
-0.57 
-1.38 
0 
-0.20 
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55 25I-NBOMe-M (O,O-bis-demethyl-) glucuronide isomer 3 (H) 
 
6.57 
MS1 PM at m/z 576.0736 (M+H) 52 576.0725 C22H27O9NI 1.89 
MS2 FI at m/z 107.0497 
FI at m/z 276.9725 
FI at m/z 293.9988 
FI at m/z 400.0410 
FI at m/z 470.0311 
 
55 
100 
42 
46 
11 
107.0497 
276.9726 
293.9991 
400.0410 
470.0312 
C7H7O 
C9H10O2I 
C9H13O2NI 
C16H19O3NI 
C15H21O8NI 
 
0 
-0.21 
-1.04 
0 
-0.20 
56 25I-NBOMe-M (O-demethyl-) glucuronide isomer 1 (H/R) 
 
7.09 
MS1 PM at m/z 590.0888 (M+H) 30 590.0882 C23H29O9NI 1.08 
MS2 FI at m/z 91.0549 
FI at m/z 121.0653 
FI at m/z 276.9727 
FI at m/z 414.0568 
 
33 
100 
1 
31 
91.0548 
121.0653 
276.9726 
414.0566 
C7H7 
C8H9O 
C9H10O2I 
C17H21O3NI 
1.37 
-0.33 
0.52 
0.43 
57 25I-NBOMe-M (O-demethyl-) glucuronide isomer 2 (H/R) 
 
7.25 
MS1 PM at m/z 590.0887 (M+H) 40 590.0882 C23H29O9NI 0.91 
MS2 FI at m/z 91.0549 
FI at m/z 121.0653 
FI at m/z 270.1254 
FI at m/z 414.0567 
 
33 
100 
1 
34 
91.0548 
121.0653 
270.1256 
414.0566 
C7H7 
C8H9O 
C17H18O3 
C17H21O3NI 
1.37 
-0.33 
-0.72 
0.19 
58 25I-NBOMe-M (O-demethyl-) glucuronide isomer 3 (H) 
 
7.83 
MS1 PM at m/z 590.0887 (M+H) 50 590.0882 C23H29O9NI 0.91 
MS2 FI at m/z 107.0496 
FI at m/z 290.9881 
FI at m/z 308.0146 
FI at m/z 414.0567 
100 
45 
17 
33 
107.0497 
290.9882 
308.0148 
414.0566 
 
C7H7O 
C10H12O2I 
C10H15O2NI 
C17H21O3NI 
 
-0.84 
-0.37 
-0.51 
0.19 
 
59 25I-NBOMe-M (O,O-bis-demethyl-HO-) glucuronide isomer 1 (R) 
 
4.69 
MS1 PM at m/z 592.0686 (M+H) 29 592.0674 C22H27O10NI 1.98 
MS2 FI at m/z 107.0496 
FI at m/z 137.0600 
FI at m/z 416.0354 
 
24 
100 
22 
107.0497 
137.0603 
416.0359 
C7H7O 
C8H9O2 
C16H19O4NI 
-0.84 
-1.86 
-1.17 
60 25I-NBOMe-M (O,O-bis-demethyl-HO-) glucuronide isomer 2 (H/R) 
 
5.59 
MS1 PM at m/z 592.0685 (M+H) 53 592.0674 C22H27O10NI 1.81 
MS2 FI at m/z 123.0444 
FI at m/z 276.9725 
FI at m/z 293.9986 
FI at m/z 299.0771 
FI at m/z 416.0357 
 
82 
100 
46 
4 
17 
123.0446 
276.9726 
293.9991 
299.0767 
416.0359 
C7H7O2 
C9H10O2I 
C9H13O2NI 
C13H15O8 
C16H19O4NI 
 
-1.67 
-0.21 
-1.72 
1.35 
-0.45 
61 25I-NBOMe-M (O,O-bis-demethyl-HO-) glucuronide isomer 3 (R) 
 
5.87 
MS1 PM at m/z 592.0683 (M+H) 45 592.0674 C22H27O10NI 1.47 
MS2 FI at m/z 107.0496 
FI at m/z 292.9672 
FI at m/z 309.9937 
FI at m/z 416.0355 
FI at m/z 486.0261 
 
56 
100 
46 
65 
12 
107.0497 
292.9675 
309.9940 
416.0359 
486.0261 
C7H7O 
C9H10O3I 
C9H13O3NI 
C16H19O4NI 
C15H21O9NI 
 
-0.84 
-0.93 
-1.04 
-0.93 
0 
62 25I-NBOMe-M (O,O-bis-demethyl-HO-) glucuronide isomer 4 (H/R) 
 
6.27 
MS1 PM at m/z 592.0689 (M+H) 31 592.0674 C22H27O10NI 2.49 
MS2 FI at m/z 123.0444 
FI at m/z 276.9726 
FI at m/z 293.9990 
FI at m/z 416.0351 
 
100 
23 
20 
12 
123.0446 
276.9726 
293.9991 
416.0359 
C7H7O2 
C9H10O2I 
C9H13O2NI 
C16H19O4NI 
 
-1.67 
0 
-0.36 
-1.89 
63 25I-NBOMe-M (O-demethyl-HO-) glucuronide isomer 1 (H/R) 
 
6.21 
MS1 PM at m/z 606.0839 (M+H) 27 606.0831 C23H29O10NI 1.36 
MS2 FI at m/z 137.0600 
FI at m/z 276.9726 
FI at m/z 293.9989 
FI at m/z 430.0521 
100 
6 
4 
20 
137.0603 
276.9726 
293.9991 
430.0515 
C8H9O2 
C9H10O2I 
C9H13O2NI 
C17H21O4NI 
-1.86 
0 
-0.70 
1.31 
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FI at m/z 470.0315 
 
6 470.0312 C15H21O8NI 0.65 
64 25I-NBOMe-M (O-demethyl-HO-) glucuronide isomer 2 (H/R) 
 
6.50 
MS1 PM at m/z 606.0838 (M+H) 31 606.0831 C23H29O10NI 1.19 
MS2 FI at m/z 91.0549 
FI at m/z 121.0653 
FI at m/z 303.1467 
FI at m/z 430.0518 
 
35 
100 
4 
33 
91.0548 
121.0653 
303.1471 
430.0515 
C7H7 
C8H9O 
C17H21O4N 
C17H21O4NI 
1.37 
-0.33 
-1.18 
0.61 
65 25I-NBOMe-M (O-demethyl-HO-) glucuronide isomer 3 (H) 
 
6.66 
MS1 PM at m/z 606.0840 (M+H) 44 606.0831 C23H29O10NI 1.52 
MS2 FI at m/z 123.0444 
FI at m/z 290.9881 
FI at m/z 308.0147 
FI at m/z 430.0516 
 
83 
100 
43 
9 
123.0446 
290.9882 
308.0148 
430.0515 
C7H7O2 
C10H12O2I 
C10H15O2NI 
C17H21O4NI 
 
-1.67 
-0.37 
-0.18 
0.15 
66 25I-NBOMe-M (O-demethyl-HO-) glucuronide isomer 4 (H) 
 
7.30 
MS1 PM at m/z 606.0839 (M+H) 34 606.0831 C23H29O10NI 1.36 
MS2 FI at m/z 123.0444 
FI at m/z 290.9880 
FI at m/z 308.0146 
FI at m/z 430.0520 
 
100 
28 
16 
15 
123.0446 
290.9882 
308.0148 
430.0515 
C7H7O2 
C10H12O2I 
C10H15O2NI 
C17H21O4NI 
 
-1.67 
-0.71 
-0.51 
1.08 
67 25I-NBOMe-M (O-demethyl-HO-) glucuronide isomer 5 (H) 
 
7.92 
MS1 PM at m/z 606.0843 (M+H) 66 606.0831 C23H29O10NI 2.02 
MS2 FI at m/z 123.0444 
FI at m/z 290.9881 
FI at m/z 308.0145 
FI at m/z 430.0523 
 
100 
98 
27 
74 
123.0446 
290.9882 
308.0148 
430.0515 
C7H7O2 
C10H12O2I 
C10H15O2NI 
C17H21O4NI 
 
-1.67 
-0.37 
-0.83 
1.78 
68 25I-NBOMe-M (HO-) glucuronide isomer 1 (H) 
 
7.16 
MS1 PM at m/z 620.1000 (M+H) 27 620.0987 C24H31O10NI 2.05 
MS2 FI at m/z 109.0653 
FI at m/z 137.0601 
FI at m/z 313.0921 
FI at m/z 444.0689 
 
54 
100 
19 
5 
109.0653 
137.0603 
313.0923 
444.0672 
 
C7H9O 
C8H9O2 
C14H17O8 
C18H23O4NI 
0 
-1.13 
-0.78 
3.86 
69 25I-NBOMe-M (HO-) glucuronide isomer 2 (H) 
 
7.46 
MS1 PM at m/z 620.0995 (M+H) 28 620.0987 C24H31O10NI 1.25 
MS2 FI at m/z 107.0496 
FI at m/z 137.0600 
FI at m/z 313.0920 
FI at m/z 444.0668 
 
18 
100 
32 
6 
107.0497 
137.0603 
313.0923 
444.0672 
 
C7H7O 
C8H9O2 
C14H17O8 
C18H23O4NI 
-0.84 
-1.86 
-1.10 
-0.87 
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Table 3 General involvement of the CYP isoenzymes on the formation of the given 25I-NBOMe 
metabolites (+: metabolite formation; ++: most intense peak among the metabolites; -: no 
metabolite formation)  
25I-NBOMe metabolite CYP 
1A2 
CYP 
2A6 
CYP 
2B6 
CYP 
2C8 
CYP 
2C9 
CYP 
2C19 
CYP 
2D6 
CYP 
2E1 
CYP 
3A4 
CYP 
3A5 
N-demethoxybenzyl (5) + - + - - - - - ++ - 
O-demethyl isomer 1 (12) + - + - ++ + + - + - 
O-demethyl isomer 3 (14) + - + + ++ + + - + - 
Hydroxy isomer 3 (34) ++ - - - - - + - + + 
Hydroxy isomer 4 (35) - - - - - - - - ++ + 
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Table 4 25I-NBOMe and its metabolites, protonated precursor ions, characteristic MS2 and MS3 
fragment ions, retention time (RT), and detectability in rat urine (RU) or human urine (HU) by LC-
MSn SUSA after 0.1 or 0.05 mg/kg BW dose. The numbers correspond to those of Tables 1 and 2. 
No. 25I-NBOMe and its metabolites Precursor 
ions, m/z 
MS2 fragment ions [m/z] and 
relative intensity, % 
MS3 fragment ions, m/z, and 
relative intensity, %, on the ion 
given in bold 
RT, min Detected 
in urine 
sample; 
dose 
given in 
brackets 
 
1 25I-NBOMe 428 121 (8), 272 (100), 284 (12), 291 
(7), 301 (8), 306 (6) 
272: 121 (19), 135 (40), 151 
(100), 225 (23), 241 (97) 
16.04 RU (0.1) 
12 25I-NBOMe-M  
(O-demethyl-) isomer 1 
414 121 (18), 258 (17), 270 (100), 287 
(29), 289 (30), 306 (19) 
270: 133 (23), 149 (100), 162 
(34), 239 (80) 
14.97 HU 
16 25I-NBOMe-M 
(O,O-bis-demethyl-HO-) isomer 2 
416 277 (65), 294 (100) 277: 135 (54), 150 (100) 
294: 135 (21), 150 (93), 262 (100) 
11.17 HU 
29 25I-NBOMe-M  
(O-demethyl-HO-) isomer 5 
430 276 (5), 291 (100), 308 (71) 291: 149 (36), 164 (78), 261 (100) 
308: 149 (8), 164 (16), 276 (100) 
14.54 HU 
50 25I-NBOMe-M 
(O-demethyl-) sulfate 
494 270 (4), 397 (9), 414 (100) 397: 121 (46), 270 (100) 
414: 121 (27), 258 (17), 270 (100) 
13.70 HU 
53 25I-NBOMe-M 
(O,O-bis-demethyl-)  
glucuronide isomer 1 
576 256 (14), 383 (8), 400 (100) 256: 148 (100) 
400: 121 (37), 256 (100), 275 (37) 
8.34 RU (0.1) 
RU (0.05) 
54 25I-NBOMe-M 
(O,O-bis-demethyl-)  
glucuronide isomer 2 
576 277 (24), 294 (39), 400 (100), 470 
(18) 
294: 135 (12), 150 (42), 262 (100) 
400: 277 (36), 294 (100) 
10.22 HU 
55 25I-NBOMe-M 
(O,O-bis-demethyl-)  
glucuronide isomer 3 
576 277 (33), 294 (51), 400 (100), 470 
(19) 
294: 135 (17), 150 (100), 262 (57) 
400: 277 (49), 294 (100) 
10.61 HU 
56 25I-NBOMe-M  
(O-demethyl-)  
glucuronide isomer 1 
590 258 (4), 270 (5), 414 (100) 414: 121 (97), 258 (79), 270 
(100), 292 (32) 
12.24 RU (0.1) 
HU 
57 25I-NBOMe-M  
(O-demethyl-)  
glucuronide isomer 2 
590 258 (3), 270 (20), 397 (9), 414 
(100) 
414: 121 (27), 258 (22), 270 
(100), 287 (31), 289 (33), 306 (24) 
12.61 HU 
61 25I-NBOMe-M 
(O,O-bis-demethyl-HO-) 
glucuronide isomer 3 
592 293 (25), 310 (37), 416 (100), 486 
(10) 
310: 166 (14), 278 (100) 
416: 277 (6), 293 (58), 310 (100) 
9.32 RU (0.1) 
64 25I-NBOMe-M  
(O-demethyl-HO-)  
glucuronide isomer 2 
606 286 (16), 303 (19), 430 (100) 303: 121 (19), 178 (100), 274 (55) 
430: 178 (17), 274 (20), 286 
(100), 303 (65) 
10.91 RU (0.1)  
RU (0.05) 
65 25I-NBOMe-M  
(O-demethyl-HO-)  
glucuronide isomer 3 
606 276 (30), 291 (100), 308 (83), 430 
(70) 
291: 149 (33), 164 (63), 261 (100) 
308: 149 (6), 164 (35), 276 (100) 
11.75 HU 
66 25I-NBOMe-M  
(O-demethyl-HO-)  
glucuronide isomer 4 
606 276 (11), 291 (48), 308 (40), 430 
(100) 
291: 149 (22), 164 (97), 261 (100) 
430: 276 (5), 291 (100), 308 (74) 
12.88 HU 
69 25I-NBOMe-M  
(HO-) glucuronide isomer 2 
620 288 (35), 313 (83), 444 (100) 313: 107 (8), 109 (8), 137 (100) 
444: 137 (75), 288 (100), 306 (16) 
13.27 HU 
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Table 5 25I-NBOMe and its metabolites, calculated masses of their precursor ions, retention times 
(RT) recorded in rat urine after the given dose or human urine by LC-HR-MS/MS SUSA The 
numbers correspond to those of Tables 1 and 2 (D = detection of the accurate mass precursor ion in 
HR full scan, I = identification via HR full scan and MS2) 
No. 25I-NBOMe and its metabolites Calculated exact 
masses of 
precursor ions, 
m/z 
RT, min Human 
urine 
Rat urine 
4 mg/kg 
BW 
Rat urine 
0.1 mg/kg 
BW 
Rat urine 
0.05 mg/kg 
BW 
1 25I-NBOMe 428.0717 6.77 D I I - 
4 25I-NBOMe-M 
(N-demethoxybenzyl-deamino-
HOOC-O-demethyl-) 
306.9467 5.79 D I D D 
7 25I-NBOMe-M 
(O,O-bis-demethyl-) isomer 1 
400.0404 5.16 D I D D 
8 25I-NBOMe-M 
(O,O-bis-demethyl-) isomer 2 
400.0404 5.73 I I - - 
12 25I-NBOMe-M 
(O-demethyl-) isomer 1 
414.0561 6.12 I I D D 
16 25I-NBOMe-M 
(O,O-bis-demethyl-HO-) isomer 2 
416.0353 5.05 I - - - 
26 25I-NBOMe-M 
(O-demethyl-HO-) isomer 2 
430.0510 5.62 I I - - 
44 25I-NBOMe-M 
(O,O,O-tris-demethyl-)  
sulfate isomer 1 
465.9816 4.54 - I D - 
45 25I-NBOMe-M 
(O,O,O-tris-demethyl-)  
sulfate isomer 2 
465.9816 4.73 D I - - 
47 25I-NBOMe-M 
(O,O-bis-demethyl-)  
sulfate isomer 1 
479.9972 5.17 I I D D 
48 25I-NBOMe-M 
(O,O-bis-demethyl-)  
sulfate isomer 2 
479.9972 5.73 D - - - 
50 25I-NBOMe-M 
(O-demethyl-) sulfate 
494.0129 6.16 I - - - 
52 25I-NBOMe-M 
(O,O,O-tris-demethyl-) 
glucuronide 
562.0569 4.03 - I D D 
53 25I-NBOMe-M 
(O,O-bis-demethyl-)  
glucuronide isomer 1 
576.0725 4.45 D I I D 
54 25I-NBOMe-M 
(O,O-bis-demethyl-)  
glucuronide isomer 2 
576.0725 5.10 D I D D 
55 25I-NBOMe-M 
(O,O-bis-demethyl-)  
576.0725 5.20 D - - - 
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glucuronide isomer 3 
56 25I-NBOMe-M 
(O-demethyl-)  
glucuronide isomer 1 
590.0882 5.52 I I D D 
57 25I-NBOMe-M 
(O-demethyl-)  
glucuronide isomer 2 
590.0882 5.68 I I - - 
58 25I-NBOMe-M 
(O-demethyl-)  
glucuronide isomer 3 
590.0882 5.98 D I - - 
61 25I-NBOMe-M 
(O,O-bis-demethyl-HO-) 
glucuronide isomer 3 
592.0674 4.77 - I D D 
63 25I-NBOMe-M 
(O-demethyl-HO-)  
glucuronide isomer 1 
606.0831 5.01 D I - - 
64 25I-NBOMe-M 
(O-demethyl-HO-)  
glucuronide isomer 2 
606.0831 5.16 D I I D 
65 25I-NBOMe-M 
(O-demethyl-HO-)  
glucuronide isomer 3 
606.0831 5.29 I - - - 
66 25I-NBOMe-M 
(O-demethyl-HO-)  
glucuronide isomer 4 
606.0831 5.65 D - - - 
67 25I-NBOMe-M 
(O-demethyl-HO-)  
glucuronide isomer 5 
606.0831 6.07 D - - - 
68 25I-NBOMe-M 
(HO-) glucuronide isomer 1 
620.0987 5.58 D - - - 
69 25I-NBOMe-M 
(HO-) glucuronide isomer 1 
620.0987 5.82 I - - - 
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Legends to Figures: 
 
Fig. 1 HR-MS/MS spectra, proposed structures (unclear O-demethylation or hydroxylation 
positions are indicated by tildes), and predominant fragmentation patterns of 25I-NBOMe and its 
phase I metabolites arranged according to precursor mass (PM) 
 
Fig. 2 Structures of 25I-NBOMe (1) and potential products (1a-c) of the postulated rearrangement 
reaction 
 
Fig. 3 HR-MS/MS spectra, proposed structures (unclear O-demethylation or hydroxylation 
positions are indicated by tildes), and predominant fragmentation patterns of 25I-NBOMe and its 
phase II metabolites arranged according to precursor mass (PM) 
 
Fig. 4 Metabolic pathways of 25I-NBOMe in human (H) and rat (R). Phase II metabolites: 
glucuronides (G), sulfates (S), glutathione conjugates (GSH), acetyl conjugates (AC), O-methyl 
conjugates (ME). Undefined position of O-demethylation or hydroxylation indicated by tildes. 
 
Fig. 5 Reconstructed ion chromatograms of the given exact masses indicating the identified 
metabolites in the human urine by LC-HR-MS/MS SUSA (peak numbering according to Tables 1 
and 2)  
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Fig. 1 HR-MS/MS spectra, proposed structures (unclear O-demethylation or hydroxylation positions are 
indicated by tildes), and predominant fragmentation patterns of 25I-NBOMe and its phase I metabolites 
arranged according to precursor mass (PM)  
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Fig. 1 continued  
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Fig. 2 Structures of 25I-NBOMe (1) and potential products (1a-c) of the postulated rearrangement reaction  
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Fig. 3 HR-MS/MS spectra, proposed structures (unclear O-demethylation or hydroxylation positions are 
indicated by tildes), and predominant fragmentation patterns of 25I-NBOMe and its phase II metabolites 
arranged according to precursor mass (PM)  
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Fig. 3 continued  
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Fig. 4 Metabolic pathways of 25I-NBOMe in human (H) and rat (R). Phase II metabolites: glucuronides (G), 
sulfates (S), glutathione conjugates (GSH), acetyl conjugates (AC), O-methyl conjugates (ME). Undefined 
position of O-demethylation or hydroxylation indicated by tildes  
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Fig. 5 Reconstructed ion chromatograms of the given exact masses indicating the identified metabolites in 
the human urine by LC-HR-MS/MS SUSA (peak numbering according to Tables 1 and 2)  
343x193mm (122 x 122 DPI)  
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